Syndax Announces Participation at Two Upcoming Investor Conferences
- None.
- None.
- A fireside chat at TD Cowen's 44th Annual Health Care Conference at 9:50 a.m. ET on Monday, March 4, 2024 in
Boston, MA - A corporate panel discussion on leukemia at TD Cowen's 44th Annual Health Care Conference at 12:50 p.m. ET on Monday, March 4, 2024 in
Boston, MA - A fireside chat at the Barclays Global Healthcare Conference at 8:30 a.m. ET on Tuesday, March 12, 2024 in
Miami, FL
A live webcast of these sessions can be accessed from the Investor section of the Company's website at www.syndax.com, where a replay will also be available for a limited time.
About Syndax
Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib, a highly selective inhibitor of the menin–KMT2A binding interaction, and axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. For more information, please visit www.syndax.com or follow the Company on X (formerly Twitter) and LinkedIn.
Syndax Contacts
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
View original content:https://www.prnewswire.com/news-releases/syndax-announces-participation-at-two-upcoming-investor-conferences-302070276.html
SOURCE Syndax Pharmaceuticals, Inc.
FAQ
When will Syndax Pharmaceuticals participate in investor conferences?
What is the purpose of the fireside chat at TD Cowen's 44th Annual Health Care Conference?
Where can the live webcast of the sessions be accessed?
